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SUMMARY. Lamivudine has been demonstrated safe and
efficacious in the short term in a large cohort of children
with chronic hepatitis B (CHB), but optimal duration of
treatment has not been elucidated and limited data on the
safety of long-term lamivudine administration have been
reported. In addition, the durability of favourable thera-
peutic outcomes after lamivudine therapy in children has
not been well characterized. The aim of this study was to
examine the safety of lamivudine and the durability of
clinical responses in a group of children who received up
to 3 years of treatment for CHB. One hundred and fifty-
one children from centres in nine countries who had
previously received lamivudine in a large prospective trial
were enrolled. During the first year, children had been
randomized to either lamivudine or placebo treatment.
Subsequently, in a separate extension study, those who
remained hepatitis B e antigen (HBeAg) positive were gi-
ven lamivudine for up to 2 years and those who were
HBeAg negative were observed for additional 2 years.
Results of these studies have been previously reported.
In this study, these children were followed for 2 additional
years. Data gathered from medical record review included
weight, height, signs and symptoms of hepatitis, alanine
aminotransferase (ALT) levels, serologic markers, hepatitis
B virus (HBV) DNA levels and serious adverse events
(SAEs). Other pharmacological treatments for CHB were
allowed according to the practices of individual investi-
gators and were documented. Subjects were divided into
two groups for analysis, those who had achieved virolog-
ical response (VR), defined as HBeAg negative and unde-
tectable HBV DNA by the bDNA assay by the end of the
extension study at 3 years, and those who had not.
In those who had achieved VR by the end of the extension
study, long-term durability of HBeAg seroconversion was
82% and >90% in those who had received lamivudine for
52 weeks and at least 2 years respectively. This compares
to 75% for those who had achieved seroconversion after
placebo. In those who had not achieved VR by the end of
the extension study, an additional 11% did so by the end
of the study; they had all received lamivudine in the
previous trial, and none had received further treatment
during the study. Eight children lost hepatitis B surface
antigen during the study and all had received lamivudine
at some point during the previous trials. Evaluation of
safety data revealed no SAEs related to lamivudine. There
was no effect of treatment on weight or height z scores.
Clinically benign ALT flares (>10 times normal) were seen
in 2% of children. Favourable outcomes from lamivudine
treatment of CHB in children are maintained for at least
several years after completion of treatment. Up to 3 years
of lamivudine treatment is safe in children.
Keywords: adolescent, child, hepatitis B, lamivudine,
treatment.
INTRODUCTION
Despite the availability of a safe and highly effective vaccine,
hepatitis B virus (HBV) infection remains a global health
problem. Even in countries where infant and childhood
immunization is recommended, there are still new cases
each year. These cases occur in high-risk subgroups, such as
i.v. drug users and homosexual men, as well as in commu-
nities with large numbers of immigrants from areas of the
world where HBV is still highly endemic. It is in this latter
group that most new childhood infections are found, either
Abbreviations: ALT, alanine aminotransferase; anti-HBe, hepatitis B
e antibody; CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen;
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; PCR, polymerase chain reaction; SAEs,
serious adverse events; ULN, upper limit of normal; VR, virological
response.
Correspondence: Maureen M. Jonas MD, Division of Gastroentero-
logy, Childrens Hospital Boston, 300 Longwood Avenue, Boston,
MA 02115, USA. E-mail: maureen.jonas@childrens.harvard.edu
*See Appendix.
Journal of Viral Hepatitis, 2008, 15, 20–27 doi:10.1111/j.1365-2893.2007.00891.x
 2007 The Authors
Journal compilation  2007 Blackwell Publishing Ltd
in the immigrant children themselves, children born to
immigrant women who are infected, or children who acq-
uire HBV by horizontal transmission within these house-
holds.
Chronic hepatitis B (CHB) in children is most often
asymptomatic and most children with the infection are
clinically well and develop normally. A small number have
significant liver disease during childhood or adolescence.
However, serious complications such as cirrhosis or hepa-
tocellular carcinoma (HCC) later in life may be expected in
approximately 25% of individuals who acquired infection
during infancy or childhood [1]. For this reason, treatment
of CHB infection is indicated in some children.
The safety and efficacy of lamivudine for 1 year in chil-
dren 2 years of age or older has been established [2].
In addition, further serologic and virologic responses (VR),
such as hepatitis B e antigen (HBeAg) seroconversion
and undetectable HBV DNA levels, have been reported in
children on long-term therapy with 2 additional years of
treatment [3]. Lamivudine-associated responses have shown
durability comparable with those observed in subjects who
underwent spontaneous seroconversion during placebo
treatment [3]. This study was undertaken to obtain addi-
tional clinical information on children who had undergone
extended lamivudine therapy in previous studies. In partic-
ular, this study was designed to collect information on the
natural history of CHB in children during and following
lamivudine therapy, as well as relevant long-term safety
data in this group.
SUBJECTS AND METHODS
This was a multicenter study conducted at 21 centres in the
United States, Canada, Europe and South America. The co-
hort for this study originally participated in a 1-year ran-
domized, placebo-controlled trial of lamivudine for 52 weeks
[2], after which, based on their HBeAg response at week 48,
subjects were enrolled in an additional extension study and
stratified to either treatment with lamivudine or observation
for 2 additional years [3]. All subjects who had participated
in the extension study were considered eligible for this study.
Subjects could receive continued treatment with lamivudine
or another agent for HBV at the discretion of the individual
investigators. Because the children had been observed for
3 years on the first two studies, and an additional 2 years in
the current study [Month 12 (Year 4) and Month 24 (Year
5)], a total of 5 years of follow-up is provided.
Data recorded for this study were based on retrospective
review of medical records for the 2 years following comple-
tion of the extension study. Baseline demographic informa-
tion was recorded from the last visit in the previous
extension study. All measurements were collected from the
visits closest to each scheduled medical record review, but
windows of up to 6 months between visits and record re-
views were allowed. Signs and symptoms of CHB were noted.
Biochemical and virologic data included serum alanine
aminotransferase (ALT) levels, HBV DNA levels, HBeAg,
hepatitis B e antibody (anti-HBe), and hepatitis B surface
antigen (HBsAg) results. Pharmacologic treatment for CHB
was documented. Serious adverse events (SAEs) and the
proportion of subjects with abnormal laboratory values for
ALT and total bilirubin were summarized. NonSAEs infor-
mation was not collected.
In the previous studies, HBV DNA was determined using a
bDNA assay (Bayer Quantiplex Version 1, lower limit of
detection 0.7 mEq ⁄mL) performed at a central laboratory. In
this study, the participating sites used locally available HBV
DNA assays. A polymerase chain reaction (PCR) based assay
was used for 70% of the subjects at month 12 and for 79% of
the subjects at month 24. The use of the more sensitive PCR-
based assays makes comparison across the studies somewhat
problematic, but does provide an assessment of HBV DNA
status at the long-term time points of this study.
DATA ANALYSIS
The population analysed was the modified intent-to-treat
which consisted of all subjects who participated without
premature discontinuation from the 2 year extension study.
This study was an observational study, during which sub-
jects may have taken lamivudine or other anti-HBV treat-
ment for varying lengths of time. Biochemical, serologic,
virologic and safety data are provided descriptively. Because
of the nature of this study, no formal statistical testing was
performed.
At the completion of the 1-year original randomized pla-
cebo-controlled trial, subjects had been assigned in the
extension study to either stratum A for continued lamivu-
dine treatment if still HBeAg positive, or stratum B for no-
treatment observation if HBeAg negative. For the analyses of
the present study, subjects were grouped by their previous
stratum assignment and by the treatment (either lamivudine
or placebo) they had received during the original controlled
trial (Fig. 1).
Efficacy measures included HBeAg loss or seroconversion,
undetectable HBV DNA, ALT normalization and HBsAg loss
or seroconversion at months 12 and 24 of this study. These
were summarized for subjects with and without VR at the
end of the previous extension study.
RESULTS
Two hundred and sixty subjects were eligible to enroll in the
current study. Of these, 151 (58%) enrolled, 117 from
stratum A and 34 from stratum B. The strata were further
divided according to the previous treatment group of the
subjects during the initial randomized, placebo-controlled
trial (Fig. 1). The breakdown into groups and demographic
characteristics of the study population are shown in Table 1.
Six subjects withdrew from this study; five were lost to
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follow-up and one withdrew because the investigator
thought that the subjects participation was no longer nec-
essary after seroconversion.
Subjects with VR at the end of the extension study
Sixty-four subjects achieved VR by the end of the extension
study (i.e., 2 or 3 years of lamivudine, depending on treat-
ment assignment during the first year controlled study).
Data from the next 2 years of observation in the present
study (months 12 and 24) for this group are shown in
Table 2. The durability of HBeAg seroconversion with no
lamivudine therapy after a total of 4 years of observation
was 75% (3 ⁄4). In children who had seroconverted after
only 52 weeks of lamivudine, it was 82% (9 ⁄11), and in
those who had received at least 2 years of lamivudine,
durability was >90% (11 ⁄12 for the previous placebo arm
and 16 ⁄17 for the previous lamivudine arm). Of the 27
subjects from stratum A with HBeAg seroconversion at
month 24, HBV DNA was undetectable in eight subjects,
detectable in seven subjects and unavailable in 12 subjects.
All seven subjects with detectable HBV DNA had low virus
levels as measured by the local assays. Of the 12 subjects
from stratum B with HBeAg seroconversion at month 24,
HBV DNA was undetectable in three subjects, detectable in
six, and unavailable in three. All six subjects with detectable
HBV DNA had low virus levels with the exception of one
subject who had an HBV DNA level of 2 · 105 copies ⁄mL.
Extension Study 2, Stratum A,
HBeAg+ve subjects
2 years open-label lamivudine
Study 1
Randomized to lamivudine or placebo for 
1 year, N=288
Extensnion Study 2, Stratum B,
HBeAg-ve subjects
2 years observation study
Previous placebo





treatment in Study 1 












treatment in Study 1 








3 (Years 4-5) 
N=27
Current Study 
3 (Years 4-5), 
N=7
Fig. 1 Origin of subjects for this
study according to treatment in
original randomized and subsequent
open-label lamivudine trials. *7 ⁄48
received additional therapy during
2-year follow-up in study 3
(lamivudine [3], interferon and
lamivudine [1], or adefovir dipivoxil
[3]. **9 ⁄69 received additional
therapy during 2-year follow-up in
study 3 (lamivudine [7], or adefovir
dipivoxil [2].
Table 1 Demographic characteristics of the study population













Age (years) [median (range)] 10.5 (5–21) 13.0 (6–22) 16.0 (9–19) 11.0 (3–19)
Gender n (%)
Female 17 (35) 31 (45) 1 (14) 5 (19)
Male 31 (65) 38 (55) 6 (86) 22 (81)
Ethnic origin n (%)
White 28 (58) 47 (68) 7 (100) 24 (89)
Asian ⁄Oriental 12 (25) 14 (20) 0 2 (7)
Black 5 (10) 4 (6) 0 0
Hispanic 2 (4) 4 (6) 0 0
Other 1 (2) 0 0 1 (4)
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This subject had received lamivudine only in the initial
controlled trial.
A high proportion of those who had received lamivudine
in previous trials maintained normal ALT levels during the
2 years of subsequent observation in both strata A and B.
In stratum A, none of the previous placebo subjects and
25% (5 ⁄20) of previous lamivudine subjects had HBsAg loss
after 2 years of observation in this study. In stratum B, none
of the previous placebo subjects and 18% (3 ⁄17) of previous
lamivudine subjects had HBsAg loss after 2 years of
observation. A similar pattern was observed for HBsAg
seroconversion.
Subjects without VR at the end of the extension study
Eighty-seven subjects did not achieve VR at the end of the
extension study (Table 3). After 12 months of observation in
this study, four of 70 (6%) subjects with available data had
Table 2 Efficacy endpoints at months 12 and 24 in children who achieved VR* at the end of the extension study














Month 12 n ⁄N 10 ⁄11 (91) 16 ⁄17 (94) 3 ⁄3 (100) 14 ⁄14 (100)
Month 24 n ⁄N 11 ⁄12 (92) 16 ⁄17 (94) 3 ⁄4 (75) 9 ⁄11 (82)
ALT normalization
Month 12 n ⁄N 11 ⁄14 (79) 13 ⁄18 (72) 2 ⁄5 (40) 18 ⁄21 (86)
Month 24 n ⁄N 13 ⁄16 (81) 15 ⁄19 (79) 2 ⁄6 (33) 16 ⁄19 (84)
HBsAg loss
Month 12 n ⁄N 0 ⁄13 2 ⁄17 (12) 0 ⁄4 4 ⁄17 (24)
Month 24 n ⁄N 0 ⁄16 5 ⁄20 (25) 0 ⁄5 3 ⁄17 (18)
HBsAg seroconversion
Month 12 n ⁄N 0 ⁄13 1 ⁄17 (6) 0 ⁄4 3 ⁄16 (19)
Month 24 n ⁄N 0 ⁄16 3 ⁄19 (16) 0 ⁄5 2 ⁄16 (13)
*Defined as loss of HBeAg and undetectable HBV DNA by the bDNA assay. Values in parentheses are indicated as percentages.
Table 3 Efficacy endpoints at months 12 and 24 in children who had not achieved VR* at the end of the extension study














Month 12 n ⁄N 1 ⁄26 (4) 3 ⁄41 (7) 0 ⁄1 0 ⁄2
Month 24 n ⁄N 4 ⁄22 (18) 3 ⁄39 (8) 0 ⁄1 0 ⁄3
HBeAg seroconversion
Month 12 n ⁄N 3 ⁄27 (11) 7 ⁄43 (16) 1 ⁄1 (100) 5 ⁄5 (100)
Month 24 n ⁄N 4 ⁄21 (19) 9 ⁄42 (21) 1 ⁄1 (100) 3 ⁄3 (100)
ALT normalization
Month 24 n ⁄N 10 ⁄28 (36) 11 ⁄47 (23) 0 ⁄1 5 ⁄5 (100)
Month 24 n ⁄N 16 ⁄28 (57) 15 ⁄46 (33) 1 ⁄1 (100) 5 ⁄6 (83)
HBsAg loss
Month 12 n ⁄N 1 ⁄19 (5) 1 ⁄38 (3) 0 ⁄1 0 ⁄5
Month 24 n ⁄N 1 ⁄21 (5) 0 ⁄41 0 ⁄1 0 ⁄6
HBsAg seroconversion
Month 12 n ⁄N 0 ⁄19 0 ⁄38 0 ⁄1 0 ⁄5
Month 24 n ⁄N 0 ⁄21 0 ⁄41 0 ⁄1 0 ⁄6
*Defined as loss of HBeAg and undetectable HBV DNA by the bDNA assay. Values in parentheses are indicated as percentages.
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achieved VR. After 24 months of observation, seven of 65
(11%) subjects with available data had achieved VR. All of
these were in stratum A, meaning that they had all received
lamivudine during the extension study, and were not in the
observation arm. None of these children who eventually
achieved VR received additional HBV treatment during this
study. At month 24, HBeAg seroconversion in stratum A
was 20% (13 ⁄63); all four subjects in stratum B had HBeAg
seroconversion at this time point.
Additional HBV treatment during this 2 year follow-up
During this observational study, a total of 16 subjects re-
ceived additional therapy for CHB at the discretion of the
investigator. Additional therapy consisted of continuation or
re-initiation of lamivudine (11 ⁄16), change to adefovir dip-
ivoxil (5 ⁄16), or a course of interferon (1 ⁄16) (this subject
took both lamivudine and interferon). Fourteen of the 16
were HBsAg positive, HBeAg positive prior to this additional
therapy and remained so at the end of this study. Two were
HBsAg positive, HBeAg negative prior to this additional
therapy and remained so at the end of the 2 years of
observation.
Safety
There were no deaths or pregnancies during this study. One
SAE was reported, a case of pharyngitis in a 10-year-old
child, judged by the investigator to be unrelated to prior
study medication use. This subject did not receive additional
treatment for CHB during this study. Summary statistics for
height and weight z scores are shown in Table 4. Baseline z
scores were calculated from data collected before the initial
lamivudine or placebo treatment. The mean and median
changes from baseline, for both weight and height, in sub-
jects who had been treated with long-term lamivudine, were
clinically insignificant, indicating no obvious effect on
weight or growth.
The prevalence of abnormal serum ALT and bilirubin
values, as well as defined ALT elevations, are reported in
Table 5 for all subjects. The highest ALT value recorded
during the observational period was used to categorize the
elevations. Any elevation of ALT was noted in 36 of 117
(31%) stratum A subjects, compared with two of 34 (6%)
stratum B subjects. Of the 36 subjects in stratum A with an
ALT elevation >2 times upper limit of normal (ULN), three
(3 ⁄117, 3%) had a severe ALT elevation (>10 · ULN)
compared with none in stratum B. None of the ALT eleva-
tions occurred in association with HBeAg seroconversion.
These same parameters are reported in Table 6 for sub-
jects who achieved VR at the end of the extension study. Any
elevation of ALT was noted in four of 37 (11%) stratum A
subjects, compared with one of 27 (4%) stratum B subjects.
Of the four subjects in stratum A with an ALT elevation,
two had mild elevations and two had moderate elevations.
Two had become HBeAg positive by month 12 of this study
(one in previous lamivudine and one in previous placebo
group) and had high levels of HBV DNA (>7 · 106 cop-
ies ⁄mL; the other two remained HBeAg negative through
month 24 and had low levels of HBV DNA (81 MEQ ⁄mL by
bDNA assay and 1140 copies ⁄mL by PCR). One subject in
stratum B who had received no lamivudine in any of the
prior studies had a mild ALT elevation. This subject was
HBeAg negative, anti-HBe positive and had undetectable
levels of HBV DNA at month 24 by PCR.
DISCUSSION
At the present time, only a-interferon and lamivudine are
licensed for use in children with CHB. The primary benefit of
a-interferon in this setting is the fixed duration of therapy.
However, a-interferon is associated with significant side
effects, including derangements of weight gain and growth
and requires parenteral administration. Lamivudine, a safe
and well-tolerated nucleoside analogue, has proven more
effective than placebo in inducing desired therapeutic out-
comes in children with HBeAg positive CHB and abnormal
ALT. Factors associated with response to lamivudine in
children include degree of pretreatment ALT elevation and
histological severity of chronic hepatitis, but not age, race,
body weight or body mass index [4]. Long-term lamivudine
therapy is associated with virologic, biochemical and histo-
logical benefits in adults and has been found to be safe [5–9].
However, in children, the optimal duration of therapy and
the safety of long-term use of this agent have not been
determined. This study is a further 2-year follow-up of
children who had received up to 3 years of continuous
lamivudine treatment in previous clinical trials. It was per-
formed to collect additional information regarding durability
of efficacy and safety in this population.
This study demonstrates that important serological out-
comes, such as HBeAg seroconversion, are usually durable
in children who achieve them while being treated with
lamivudine, up to 4 years after therapy is discontinued.
In addition, HBsAg loss and seroconversion, which occurs
very rarely in the untreated natural history of CHB, was seen
in children who received lamivudine for 1–3 years. Our
findings are consistent with a recent study in Korean chil-
dren where long-term treatment with lamivudine led to
significant improvement in the seroconversion rates of
HBeAg and HBsAg [10]. Results of several other small
studies of children receiving long-term lamivudine have,
however, reported low rates of HBeAg seroconversion and
no clearance of HBsAg [11,12]. No serious toxicity was
observed in the children.
Methodological limitations of this study include the
retrospective design and not all children who participated
in the previous randomized and open-label therapy trials
were enrolled. The latter limitation is because investigators
at some sites chose not to participate and not every
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subject at the participating sites consented to the long-
term follow-up. However, there was no obvious selection
bias in those who chose to participate and at least 50%
enrolment was achieved from each of the stratified treat-
ment groups.
Assessment of the durability of VR, which includes
HBeAg loss and undetectable HBV DNA, is confounded in
this study by use of multiple HBV DNA assays with
varying sensitivities. Subjects who had undetectable HBV
DNA by the bDNA assay used in the earlier studies, then
Table 4 Weight for age and height for age z-scores at baseline and at months 12 and 24 of observation (before either
lamivudine or placebo treatment)















n 47 69 7 27
Median 0.04 )0.13 )0.41 0.02
Range )4.06 to 3.46) )3.41 to 2.32 )1.97 to 0.56 )2.13 to 9.07
Month 12
n 36 56 6 25
Median )0.02 )0.24 0.10 )0.26
Range )4.29 to 3.05 )4.04 to 2.20 )1.58 to 0.79 )2.42 to 3.33
Change from baseline
n 35 56 6 25
Median )0.19 )0.13 0.33 )0.34
Range )1.45 to 2.42 )2.00 to 2.24 0.23–1.56 )5.74 to 0.64
Month 24
n 35 57 7 21
Median )0.57 )0.29 0.16 )0.40
Range )2.51 to 2.01 )3.91 to 1.98 )1.10 to 1.38 )2.33 to 3.13
Change from baseline
n 34 57 7 21
Median )0.32 )0.12 0.87 )0.57
Range )1.40 to 1.98 )1.62 to 2.45 0.05–1.89 )5.94 to 1.31
Height z-scores
Baseline
n 47 69 7 26
Median )0.27 )0.05 )0.96 )0.26
Range )2.18 to 8.58 )2.87 to 9.71 )1.52 to 0.68 )2.10 to 1.54
Month 12
n 36 56 6 24
Median )0.45 )0.25 0.03 )0.14
Range )2.95 to 2.10 )4.39 to 2.86 )1.15 to 1.35 )2.23 to 7.12
Change from baseline
n 35 56 6 23
Median )0.09 )0.16 0.49 )0.20
Range )1.60 to 1.99 )8.91 to 1.73 0.20–1.11 )2.58 to 1.83
Month 24
n 35 56 6 20
Median )0.62 )0.13 0.11 0.04
Range )2.10 to 2.08 )4.27 to 3.11 )1.14 to 1.21 )2.44 to 5.85
Change from baseline
n 34 56 6 19
Median )0.17 )0.26 0.73 )0.46
Range )1.29 to 1.36 )9.21 to 3.36 0.32–2.25 )2.31 to 0.90
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found to have very low levels of HBV DNA by PCR-based
assays during this 2 year period, would have to be char-
acterized in this study as having lost response, a desig-
nation which may not be clinically significant. However, a
high proportion of subjects maintained HBeAg serocon-
version and ALT normalization within the 2 year obser-
vation period, regardless of original treatment assignment
or stratum in the long-term treatment trial. This suggests
that seroconversion associated with lamivudine treatment
is as durable as spontaneous seroconversion in children.
The duration of required consolidation treatment, i.e.,
continuation of lamivudine after HBeAg seroconver-
sion, could not be determined for individual subjects
from this study, as treatment was continued for most
subjects in the original studies after seroconversion oc-
curred.
Some children with CHB should be considered for
treatment, especially if ALT is persistently abnormal,
Table 5 Alanine aminotransferase (ALT) and bilirubin values outside the normal range at months 12 and 24 and defined ALT
elevations













ALT >ULN n (%)
Month 12 21 ⁄42 (50) 42 ⁄66 (64) 4 ⁄6 (67) 3 ⁄26 (12)
Month 24 15 ⁄44 (34) 36 ⁄66 (55) 4 ⁄7 (57) 4 ⁄25 (16)
Bilirubin > ULN n (%)
Month 12 4 ⁄31 (13) 7 ⁄54 (13) 2 ⁄4 (50) 1 ⁄21 (5)
Month 24 3 ⁄29 (10) 11 ⁄44 (25) 2 ⁄5 (40) 1 ⁄19 (5)
Defined ALT elevations*
Any elevation n (%) 13 (27) 23 (33) 1 (14) 1 (4)
Mild elevation n (%) (2 · ULN–5 · ULN) 7 (54) 16 (70) 1 (100) 1 (100)
Moderate elevation n (%)
(5 · ULN to ‡10 · ULN)
4 (31) 6 (26) 0 0
Severe elevation n (%) (>10 · ULN) 2 (15) 1 (4) 0 0
*Highest ALT value at any time during the study.
Table 6 Alanine aminotransferase (ALT) and bilirubin values outside the normal range at months 12 and 24 and defined ALT
elevations in subjects who achieved VR at the end of the extension study













ALT >ULN n (%)
Month 12 3 ⁄14 (21) 6 ⁄19 (32) 3 ⁄5 (60) 3 ⁄21 (14)
Month 24 3 ⁄16 (19) 5 ⁄20 (25) 4 ⁄6 (67) 3 ⁄19 (16)
Bilirubin > ULN n (%)
Month 12 1 ⁄10 (10) 5 ⁄14 (36) 1 ⁄3 (33) 1 ⁄17 (6)
Month 24 0 ⁄10 4 ⁄10 (40) 1 ⁄4 (25) 1 ⁄14 (7)
Defined ALT elevations*
Any elevation n (%) 2 (13) 2 (10) 1 (17) 0
Mild elevation (2 · ULN–5 · ULN) n (%) 1 (50) 1 (50) 1 (100) 0
Moderate elevation (5 · ULN to ‡10 · ULN) 1 (50) 1 (50) 0 0
Severe elevation (>10 · ULN) n (%) 0 0 0 0
*Highest ALT value at any time point during the study.
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indicating immune activation and the potential for hepatic
injury. The duration of viral replication associated with
hepatic injury is most likely proportional to the likelihood
of complications such as cirrhosis and HCC. Treatment
during childhood should be aimed at shortening this time
period, as signified by normalization of ALT, disappearance
of serum HBV DNA and HBeAg seroconversion. Although
monitoring for resistance should be considered, as resis-
tance to lamivudine is associated with a very low rate of
subsequent therapeutic responses [3,13], lamivudine is a
safe and effective option for up to 3 years for the treat-
ment of children with CHB.
APPENDIX
In addition to the authors, participating members of the
International Pediatric Lamivudine Investigator Group in-
clude the following: E. M. Alonso, Childrens Memorial
Hospital, Chicago; F. Alvarez, Hoˆpital Ste.-Justine, Mon-
treal; J Areias, Hospital General Santo Anto´nio, Porto,
Portugal; I. Badia, Hospital General de Nin˜os, Buenos
Aires, Argentina; G. Cordeiro Ferreira, Hospital Fernando
da Fonseca, Amadora, Portugal; D. Gremse, University of
South Alabama, Mobile; B. Haber, Childrens Hospital of
Philadelphia, Philadelphia; D. Kelly, Birmingham Chil-
drens Hospital, Birmingham, UK; N Manolaki, Agia Sofia
Childrens Hospital, Athens, Greece; J. Mizerski, John Paul
II Hospital, Krakow, Poland; P. Mohan, Childrens Na-
tional Medical Center, Washington, D.C.; J. Molleston,
James Whitcomb Riley Hospital for Children, Indianapolis;
K. Murray, Childrens Hospital and Regional Medical
Center, Seattle; I. Po´, Hospital Dona Estefaˆnia, Lisbon,
Portugal; G. Porta, Instituto da Crianc¸a Prof. Pedro de
Alcaˆntara, Sa˜o Paolo, Brazil; N. Rodriguez-Baez, Childrens
Medical Center of Dallas, Dallas; K. Schwarz, Johns
Hopkins Hospital, Baltimore; E. Sokal, Clinique Universi-
taire St-Luc, Brussells, Belgium; W. Sluzewski, Klinica
Obserwacyjno-Zakazna, Poznan, Poland; M. Woynarowski,
Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw,
Poland.
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